Product Information
Ristocetin, which was introduced in to clinical medicine as an antibiotic in the 1950's, was subsequently withdrawn, in part, because it caused thrombocytopenia. It was later demonstrated that this drug would aggregate (more strictly agglutinate) platelets in-vitro. In an unknown fashion, the antibiotic ristocetin causes von Willibrand factor to bind the platelet receptor glycoprotein Ib (GpIb), so when ristocetin is added to normal blood, it causes agglutination. In von Willebrand disease, where von Willebrand factor is absent or defective, abnormal agglutination occurs. The ristocetin induced platelet aggregation (RIPA) is an in vitro assay for von Willebrand factor activity used to diagnose von Willebrand disease. It can be used in the diagnosis of type 2B vWD and Bernard-Soulier syndrome.
A lyophilised preparation of 10mg/ml Ristocetin sulphate with buffers and stabilisers
1 x 1ml
